Payment overview · 2025
General Payments
$886.69
35 reported records · 13 companies
Healthcare provider profile · identity verified
Justin David Moellinger, M.D.
Allopathic & Osteopathic Physicians|Surgery · BESSEMER, AL · NPI 1134290984
Verified facts
What the public records show
CMS Open Payments records show Justin David Moellinger, M.D. received $886.69 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Dalvance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DALVANCE as an associated drug or biological on 20326 records involving 8863 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Dalvance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $330.13 | 37.2% | 15 | 2025 |
| Avita Medical Americas, LLC | Unresolved — no canonical attribution shown | $114.34 | 12.9% | 4 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $75.81 | 8.6% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$67.33 | 7.6% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $48.99 | 5.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $44.23 | 5.0% | 1 | 2025 |
| Biocomposites Inc | Unresolved — no canonical attribution shown | $40.79 | 4.6% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $40.08 | 4.5% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $39.96 | 4.5% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $25.98 | 2.9% | 1 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $22.83 | 2.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21.70 | 2.5% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $14.52 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $886.69 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $203.11 | 11 | 2025 |
Source payment records
|
|||||
| STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS Normalized: strattice reconstructive tissue matrix bps |
Device | ABBVIE INC. | $127.02 | 4 | 2025 |
Source payment records
|
|||||
| Cohealyx Normalized: cohealyx |
Device | Avita Medical Americas, LLC | $114.34 | 4 | 2025 |
Source payment records
|
|||||
| Permeaderm Normalized: permeaderm |
Device | Avita Medical Americas, LLC | $114.34 | 4 | 2025 |
Source payment records
|
|||||
| Recell Normalized: recell |
Device | Avita Medical Americas, LLC | $114.34 | 4 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $108.08 | 6 | 2025 |
Source payment records
|
|||||
| MAXTACK Normalized: maxtack |
Device | Medtronic, Inc. | $67.33 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $48.99 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $48.99 | 2 | 2025 |
Source payment records
|
|||||
| SpyGlass Discover Normalized: spyglass discover |
Device | Boston Scientific Corporation | $44.23 | 1 | 2025 |
Source payment records
|
|||||
| Stimulan Normalized: stimulan |
Device | Biocomposites Inc | $40.79 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $40.08 | 2 | 2025 |
Source payment records
|
|||||
| FLUENT FLUID MANAGEMENT SYSTEM Normalized: fluent fluid management system |
Device | Hologic Sales and Service, LLC | $25.98 | 1 | 2025 |
Source payment records
|
|||||
| MYOSURE TISSUE REMOVAL DEVICE Normalized: myosure tissue removal device |
Device | Hologic Sales and Service, LLC | $25.98 | 1 | 2025 |
Source payment records
|
|||||
| NOVASURE Normalized: novasure |
Device | Hologic Sales and Service, LLC | $25.98 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS GO v2 HOME Normalized: renasys go v2 home |
Device | Smith+Nephew, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| URGOCLEAN AG Normalized: urgoclean ag |
Device | Urgo Medical North America, LLC | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| DALVANCE dalvance |
2025 | Dalvance | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | DALVANCE open payments reported associated product |
CMS Open Payments — General Payments 20326 supporting records · 8863 recipient NPIs · example record 1201352826 |
Dalvance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 80 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 73 |
| Meropenem | Meropenem | 83 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 74 | suppressed |
| Daptomycin | Daptomycin | 66 | suppressed |
| Ondansetron Odt | Ondansetron | 59 | 52 |
| Levofloxacin | Levofloxacin | 54 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 18 |
| Dalvance | Dalbavancin Hcl | 27 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $886.69 · 35 records | ABBVIE INC. | ACTIV.A.C., COLLAGENASE SANTYL, Cohealyx, DALVANCE, FLUENT FLUID MANAGEMENT SYSTEM, JOURNAVX, Kerecis GraftGuide, Kerecis SurgiClose, MAXTACK, MYOSURE TISSUE REMOVAL DEVICE, NOVASURE, Permeaderm, RENASYS GO v2 HOME, Recell, STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS, SpyGlass Discover, Stimulan, TEFLARO, URGOCLEAN AG, VISTASEAL | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Dalvance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error